← Companies|Reaction Biology
Re

Reaction Biology

Malvern PAFounded 2001100 employees
Private CapbiotechPrivateOncology
Platform: Assay Services
Market Cap
N/A
All Drugs
2
Clinical Trials
6
Failed / Terminated
2
FDA Approved
0
Drug Pipeline (2 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
REA-6162REA-6162Preclinical2Cell TherapyJAK2SHP2iFTD
LisoderotideREA-3450Phase 34Gene EditingTNFαIL-13iFTDUrothelial Ca
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (6)
2025-07-07
Lisoderotide Ph3 Readout
Urothelial Ca
Past
2028-12-04
REA-6162 Interim
FTD
Interim
2029-01-19
Lisoderotide Ph3 Readout
Urothelial Ca
Ph3 Readout
2030-03-02
Lisoderotide Ph3 Readout
Urothelial Ca
Ph3 Readout
2030-05-04
Lisoderotide Ph3 Readout
FTD
Ph3 Readout
2031-09-08
REA-6162 Interim
FTD
Interim